...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith Shareholders

 0.89%  Charalambos Katevatis  1,200,001 $300.0k 0% ???

They're still being confused with this other company!

0.89% Charalambos Katevatis 1,200,001 $300.0k 0%

https://www.pressreader.com/canada/stockwatch-daily/20210819/281505049295814

Share
New Message
Please login to post a reply